{"DataElement":{"publicId":"5607584","version":"1","preferredName":"Glioblastoma RANO Criteria Response Date","preferredDefinition":"Date of response based on Response Assessment in Neuro-Oncology Criteria Response (RANO) criteria for Glioblastoma.","longName":"GBM_RANO_DT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5607074","version":"1","preferredName":"Glioblastoma Response Assessment in Neuro-Oncology Criteria","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)_An update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM).","longName":"3049870v1.0:5607072v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3049870","version":"1","preferredName":"Glioblastoma","preferredDefinition":"A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.","longName":"C3058","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"838D91A3-8EB8-848A-E040-BB89AD433CBD","latestVersionIndicator":"Yes","beginDate":"2010-04-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-06","modifiedBy":"ONEDATA","dateModified":"2010-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5607072","version":"1","preferredName":"Response Assessment in Neuro-Oncology Criteria","preferredDefinition":"An update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM).","longName":"C114879","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Response Assessment in Neuro-Oncology Criteria","conceptCode":"C114879","definition":"An update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"43CDFDE8-B33C-6309-E053-F662850AB5B4","latestVersionIndicator":"Yes","beginDate":"2016-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-16","modifiedBy":"ONEDATA","dateModified":"2016-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"43CDFDE8-B34D-6309-E053-F662850AB5B4","latestVersionIndicator":"Yes","beginDate":"2016-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-16","modifiedBy":"COOPERM","dateModified":"2017-03-10","changeDescription":"Created for GBM Pembro HSPPC study in C3D as requested by Y. Yakovlev. mc 12/16/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017121","version":"1","preferredName":"CTMS Date","preferredDefinition":"Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).","longName":"CTMS_DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":"4","maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"DD/MON/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"A6545B3B-0FC3-40BF-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-07-21","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-21","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"8/30/17 jk Transferred context, added CSI and reg status, released per Round 5 finalization task. --- Display and exchange formats are based on CTMS reporting requirements v.3.02 and all subsequent versions of these guidelines.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"RANO Response Date","type":"Preferred Question Text","description":"RANO Response Date","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4404FDC6-821A-0F30-E053-F662850ADAC1","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"COOPERM","dateModified":"2017-03-10","changeDescription":"Created for GBM Pembro HSPPC protocol as requested by Y. Yakovlev. mc 12/19/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}